Novel first-in-class SGK agonists for the treatment of rare ophthalmological indications
Bionure is a clinical stage company developing first-in-class SGK agonists for the treatment of rare ophthalmological diseases for which no treatment options are nowadays available. We focus in particular in two conditions in which patients suffer from significant vision impairment: acute optic neuritis and neuromyelitis optica.
With these patients in mind, we have built an extraordinary committed team of experts in neuro-ophthalmology and neuro-inflammation, passionate about bringing meaningful therapies to society with the aim of changing the life of thousands of people.
Our lead candidate BN201 has been granted orphan designation for optic neuritis in Europe and the United States and has shown compelling evidence of neuroprotective and remyelinating activity in several animal models. Bionure is currently undertaking a Phase 1 clinical trial of the compound BN201 in the United Kindom.
The company was founded in 2009 and has its headquarters in Barcelona, Spain.
Bionure has participated in the following projects:
“Nuevas aproximaciones terapéuticas para la Esclerosis Múltiple y la Esclerosis Lateral Amiotrófica: efectos modificadores de la enfermedad y neuroprotección” (expediente IPT-010000-2010-035) lead by ADVANCED IN VITRO CELL TECHNOLOGIES SA, with the participation of NEUROTEC PHARMA SL and the CONSORCI INSTITUT D’INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER.
“STOP-ELA: Aproximación multi-tecnológica para el desarrollo de nuevas terapias y sistemas avanzados de administración farmacológica para la Esclerosis Lateral Amiotrófica” (expediente IPT-2011-1091-900000) lead by NEUROTEC PHARMA SL, with the participation of ADVANCED IN VITRO CELL TECHNOLOGIES SA, PALO BIOFARMA SL, NATAC BIOTECH SL, UNIVERSIDAD DE ZARAGOZA, and the CONSORCI INSTITUT D’INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER.
“Desarrollo de terapias neuroprotectoras para Esclerosis Múltiple” (expediente IPT-2011-1312-900000) lead by DIGNA BIOTECH SL, with the participation of the FUNDACION PRIVADA INSTITUT D’INVESTIGACIO BIOMEDICA DE BELLVITGE and the CONSORCI INSTITUT D’INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER.
These projects have received funding from the Ministry of Science and Innovation, within the National Plan for Scientific Research, Development and Technological Innovation 2008-2011. They have been co-financed by the European Regional Development Fund (ERDF).
Bionure has received non-dilutive funding support from the following local, national and european governments: